during injectable phase Moxifloxacin (400 mg, Symptomatic monitoring fixed dose) Terizidone (15-20) Symptomatic monitoring Ethionamide (15-20) Liver function tests every month Thyroid-stimulating hormone at baseline and every 6 months Adapted from the Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-resistant Tuberculosis  and the South African Department of Health Multi-drug Resistant Tuberculosis: A Policy Framework on Decentralised and Deinstitutionalised
Management for South Africa.
This paper will focus on the housing futures of people with intellectual disabilities who have been, or will be, deinstitutionalised.
The third section draws on findings from the AHURI study and presents an overview of both the current context of resettlement programs as well as the housing futures of people expected to be deinstitutionalised.
Both Landscapes of Despair (1987) and a follow up study, Malign Neglect (Wolch & Dear 1993), emphasised how poor public funding and community opposition to care facilities had contributed to a rise in homelessness amongst deinstitutionalised people.